Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FTC-146 · 1 trial · 4 indications
Biodistribution of \[18F\]FTC-146 represented as Standardized Uptake Value max (SUVmax) in pain patients.
| Arm | Type | Description |
|---|---|---|
| Pediatric Chronic Pain Patients | EXPERIMENTAL | Individuals 11-18 years old, with chronic pain (lasting at least 2 months). |
| Name | Type | Description |
|---|---|---|
| [18F]FTC-146 | DRUG | Participants will be injected with 0.08 mCi/kg \[18F\]FTC-146. A whole-body PET/MRI scan will be performed after injection. |
Inclusion Criteria: * 11-18 years old. * Chronic pain (nociceptive, neuropathic or mixed pain) lasting at least 2 months. * Pain level of at least 4/10 on a 0-10 Comparative Pain Scale (reported at time of screening). * Covid Vaccination status: Vaccinated or unvaccinated subjects who received a ne...
FTC-146 is an investigational small molecule being developed by GE HealthCare Technologies Inc. (GEHC) for chronic pain. It is currently in Phase 1 clinical development. The drug is being studied as a diagnostic agent for use in PET/MRI imaging to help identify sources of chronic pain.
FTC-146 is being studied for use in chronic pain, specifically as a diagnostic agent in PET/MRI imaging. The goal is to help identify and localize pain sources in conditions such as neuropathic pain and nociceptive pain, particularly in pediatric patients.
FTC-146 is being developed by GE HealthCare Technologies Inc., a company traded on the NYSE under the ticker GEHC. The company is conducting clinical research to evaluate the drug's potential as a diagnostic imaging agent for chronic pain.
FTC-146 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized study. The drug is investigational and has not been approved by regulatory authorities for any use.
FTC-146 has been studied in one completed Phase 1 clinical trial, identified as NCT04435821. This trial, titled "PET/MRI in the Diagnosis of Pediatric Chronic Pain," enrolled 5 participants in the United States and evaluated the drug in patients aged 11 years and older.
FTC-146 is a distinct investigational compound and is not known to be the same as any other marketed drug. It is being developed specifically as a diagnostic imaging agent for chronic pain and has no established alternative names.